Advertisement
Screener

Dianthus Therapeutics, Inc. /DE/ (DNTH) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Dianthus Therapeutics, Inc. /DE/ Operating Cash Flow

Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Operating Cash Flow of -$77.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04

  • Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$48.98M.
  • Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$28.86M.
  • Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$46.98M.
  • Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$30.55M.
  • Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) operating activities for fiscal 2025 was -$129.06M.
  • Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) operating activities for fiscal 2024 was -$78.18M.
  • Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) operating activities for fiscal 2023 was -$36.86M.
  • Dianthus Therapeutics, Inc. /DE/ net cash provided by (used in) operating activities for fiscal 2022 was -$29.07M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$48.98M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$77.84M
10-Q · filed 2026-08-04
-$124.82M
derived: sum of 3 quarters · filed 2026-08-04
-$155.38M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31-$28.86M
10-Q · filed 2026-05-05
-$75.84M
derived: sum of 2 quarters · filed 2026-05-05
-$106.39M
derived: sum of 3 quarters · filed 2026-05-05
-$130.29M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31-$46.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
-$77.54M
derived: sum of 2 quarters · filed 2026-03-09
-$101.43M
derived: sum of 3 quarters · filed 2026-08-04
-$129.06M
10-K · filed 2026-03-09
2025-09-30-$30.55M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$54.45M
derived: sum of 2 quarters · filed 2026-08-04
-$82.08M
10-Q · filed 2025-11-05
-$109.52M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30-$23.89M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
-$51.52M
10-Q · filed 2026-08-04
-$78.97M
derived: sum of 3 quarters · filed 2026-08-04
-$100.23M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$27.63M
10-Q · filed 2026-05-05
-$55.07M
derived: sum of 2 quarters · filed 2026-05-05
-$76.34M
derived: sum of 3 quarters · filed 2026-05-05
-$90.87M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31-$27.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
-$48.71M
derived: sum of 2 quarters · filed 2026-03-09
-$63.24M
derived: sum of 3 quarters · filed 2026-03-09
-$78.18M
10-K · filed 2026-03-09
2024-09-30-$21.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
-$35.80M
derived: sum of 2 quarters · filed 2025-11-05
-$50.74M
10-Q · filed 2025-11-05
-$62.59M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30-$14.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$29.47M
10-Q · filed 2025-08-07
-$41.32M
derived: sum of 3 quarters · filed 2025-08-07
-$51.31M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31-$14.94M
10-Q · filed 2025-05-12
-$26.80M
derived: sum of 2 quarters · filed 2025-05-12
-$36.79M
derived: sum of 3 quarters · filed 2025-05-12
-$41.52M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31-$11.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
-$21.85M
derived: sum of 2 quarters · filed 2025-03-11
-$26.58M
derived: sum of 3 quarters · filed 2025-03-11
-$36.86M
10-K · filed 2025-03-11
2023-09-30-$9.99M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$14.72M
derived: sum of 2 quarters · filed 2024-11-07
-$25.01M
10-Q · filed 2024-11-07
-$33.86M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30-$4.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$15.02M
10-Q · filed 2024-08-08
-$42.14M
10-Q · filed 2023-08-03
-$23.87M
derived: sum of 3 quarters · filed 2024-08-08
-$7.49M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$10.28M
10-Q · filed 2024-05-09
-$35.60M
10-Q · filed 2023-05-15
-$19.14M
derived: sum of 2 quarters · filed 2024-05-09
-$2.76M
derived: sum of 3 quarters · filed 2024-05-09
-$19.61M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$8.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
$7.52M
derived: sum of 2 quarters · filed 2024-03-21
-$9.33M
derived: sum of 3 quarters · filed 2024-03-21
-$29.07M
10-K · filed 2024-03-21
-$67.09M
10-K · filed 2023-03-23
2022-09-30$16.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$478.00K
derived: sum of 2 quarters · filed 2023-11-09
-$20.22M
10-Q · filed 2023-11-09
-$50.40M
10-Q · filed 2022-11-03
$13.72M
derived: sum of 4 quarters · filed 2023-12-21
2022-06-30-$16.85M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
-$36.59M
10-Q · filed 2023-08-03
-$2.66M
derived: sum of 3 quarters · filed 2023-12-21
-$16.72M
derived: sum of 4 quarters · filed 2023-12-21
2022-03-31-$19.74M
10-Q · filed 2023-05-15
$14.20M
derived: sum of 2 quarters · filed 2023-12-21
$129.00K
derived: sum of 3 quarters · filed 2023-12-21
-$12.87M
derived: sum of 4 quarters · filed 2023-12-21
2021-12-31$33.94M
derived: 8-K 12 month − 10-Q 9 month · filed 2023-12-21
$19.87M
derived: sum of 2 quarters · filed 2023-12-21
$6.87M
derived: sum of 3 quarters · filed 2023-12-21
-$9.90M
8-K · filed 2023-12-21
-$59.53M
10-K · filed 2022-03-08
2021-09-30-$14.07M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
-$27.07M
derived: sum of 2 quarters · filed 2022-11-03
-$43.84M
10-Q · filed 2022-11-03
-$57.57M
derived: sum of 4 quarters · filed 2022-11-03
2021-06-30-$13.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$29.77M
10-Q · filed 2022-08-04
-$43.51M
derived: sum of 3 quarters · filed 2022-08-04
-$57.94M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31-$16.77M
10-Q · filed 2022-05-16
-$30.51M
derived: sum of 2 quarters · filed 2022-05-16
-$44.94M
derived: sum of 3 quarters · filed 2022-05-16
-$64.14M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31-$13.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
-$28.16M
derived: sum of 2 quarters · filed 2022-03-08
-$47.37M
derived: sum of 3 quarters · filed 2022-03-08
-$64.02M
10-K · filed 2022-03-08
2020-09-30-$14.43M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
-$33.63M
derived: sum of 2 quarters · filed 2021-11-04
-$50.29M
10-Q · filed 2021-11-04
-$65.92M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30-$19.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
-$35.86M
10-Q · filed 2021-08-05
-$51.49M
derived: sum of 3 quarters · filed 2021-08-05
-$63.00M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31-$16.66M
10-Q · filed 2021-05-06
-$32.28M
derived: sum of 2 quarters · filed 2021-05-06
-$43.79M
derived: sum of 3 quarters · filed 2021-05-06
-$58.82M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31-$15.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03
-$27.13M
derived: sum of 2 quarters · filed 2021-03-03
-$42.17M
derived: sum of 3 quarters · filed 2021-03-03
-$57.10M
10-K · filed 2021-03-03
2019-09-30-$11.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$26.54M
derived: sum of 2 quarters · filed 2020-11-05
-$41.48M
10-Q · filed 2020-11-05
-$54.10M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30-$15.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$29.97M
10-Q · filed 2020-08-06
-$42.59M
derived: sum of 3 quarters · filed 2020-08-06
-$53.14M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31-$14.94M
10-Q · filed 2020-05-07
-$27.56M
derived: sum of 2 quarters · filed 2020-05-07
-$38.11M
derived: sum of 3 quarters · filed 2020-05-07
-$47.22M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31-$12.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03
-$23.17M
derived: sum of 2 quarters · filed 2020-03-03
-$32.28M
derived: sum of 3 quarters · filed 2020-03-03
-$41.89M
10-K · filed 2020-03-03
2018-09-30-$10.55M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13
-$19.66M
derived: sum of 2 quarters · filed 2019-11-13
-$29.26M
10-Q · filed 2019-11-13
-$37.49M
derived: sum of 4 quarters · filed 2020-03-03
2018-06-30-$9.11M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
-$18.71M
10-Q · filed 2019-08-08
-$26.95M
derived: sum of 3 quarters · filed 2020-03-03
-$32.39M
derived: sum of 4 quarters · filed 2020-03-03
2018-03-31-$9.60M
10-Q · filed 2019-05-09
-$17.84M
derived: sum of 2 quarters · filed 2020-03-03
-$23.28M
derived: sum of 3 quarters · filed 2020-03-03
2017-12-31-$8.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03
-$13.68M
derived: sum of 2 quarters · filed 2020-03-03
-$22.26M
10-K · filed 2020-03-03
2017-09-30-$5.44M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
-$14.03M
10-Q · filed 2018-11-08
2017-06-30-$8.59M
10-Q · filed 2018-08-09
2016-12-31-$6.53M
10-K · filed 2019-03-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
Erasca, Inc. (ERAS)United States$5.073B-19.96
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Veradermics, Inc (MANE)United States$4.839B
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51